Medicare AdvantagePrior AuthMedium impact
ZTlido® (lidocaine topical system) (Revised)
Humana·Dermatology, Pain Management, Neurology +3 more·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Jun 25, 2026
Summary
Humana Medicare Advantage has revised its prior authorization policy for ZTlido (lidocaine 1.8% topical system) effective January 1, 2026, with updates as of May 27, 2026. The policy requires prior authorization for three indications: post-herpetic neuralgia, chronic back pain, and hip/knee osteoarthritis pain. A critical requirement is that all members must have previous treatment with generic lidocaine 5% patch before ZTlido coverage is approved. This is a pharmacy-level prior authorization requirement.
Action Required
By January 1, 2026: Billing and pharmacy teams must implement prior authorization requirements for ZTlido topical patches through Humana Medicare Advantage plans. Specifically: (1) Update billing system to flag all ZTlido prescriptions for prior authorization before claims submission; (2) Configure system to verify member has documented prior treatment with generic lidocaine 5% patch before approval can be granted; (3) Ensure prior authorization request includes diagnosis confirmation for post-herpetic neuralgia, chronic back pain, or hip/knee osteoarthritis pain; (4) Communicate with prescribing providers that ZTlido requires prior auth and prior lidocaine 5% patch trial documentation; (5) Train front desk and billing staff on new requirement. Claims submitted without prior authorization will be denied by Humana. Update all relevant workflows, EMR templates, and provider communication materials by the effective date.